PL2214646T3 - Dendrymery do przedłużonego uwalniania związków - Google Patents

Dendrymery do przedłużonego uwalniania związków

Info

Publication number
PL2214646T3
PL2214646T3 PL08835693T PL08835693T PL2214646T3 PL 2214646 T3 PL2214646 T3 PL 2214646T3 PL 08835693 T PL08835693 T PL 08835693T PL 08835693 T PL08835693 T PL 08835693T PL 2214646 T3 PL2214646 T3 PL 2214646T3
Authority
PL
Poland
Prior art keywords
dendrimers
prolonged release
prolonged
release
release dendrimers
Prior art date
Application number
PL08835693T
Other languages
English (en)
Inventor
Kannan Rangaramanujam
Raymond Iezzi
Bharath Raja Guru
Sujatha Kannan
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of PL2214646T3 publication Critical patent/PL2214646T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/005—Dendritic macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PL08835693T 2007-10-05 2008-10-06 Dendrymery do przedłużonego uwalniania związków PL2214646T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99798707P 2007-10-05 2007-10-05
US13580908P 2008-07-23 2008-07-23
EP08835693.6A EP2214646B1 (en) 2007-10-05 2008-10-06 Dendrimers for sustained release of compounds
PCT/US2008/078988 WO2009046446A2 (en) 2007-10-05 2008-10-06 Dendrimers for sustained release of compounds

Publications (1)

Publication Number Publication Date
PL2214646T3 true PL2214646T3 (pl) 2021-12-20

Family

ID=40526988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08835693T PL2214646T3 (pl) 2007-10-05 2008-10-06 Dendrymery do przedłużonego uwalniania związków

Country Status (9)

Country Link
US (4) US10463609B2 (pl)
EP (1) EP2214646B1 (pl)
JP (1) JP5484339B2 (pl)
CA (1) CA2701291A1 (pl)
DK (1) DK2214646T3 (pl)
HU (1) HUE055815T2 (pl)
PL (1) PL2214646T3 (pl)
PT (1) PT2214646T (pl)
WO (1) WO2009046446A2 (pl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2996768C (en) * 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
JP5336382B2 (ja) * 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
WO2008131131A1 (en) * 2007-04-17 2008-10-30 Micell Technologies, Inc. Stents having biodegradable layers
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
US8505743B2 (en) * 2009-04-08 2013-08-13 Michigan Molecular Institute Surface modification of polyamide reverse osmosis membranes
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
CA2767163A1 (en) * 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
US20110189291A1 (en) * 2009-08-04 2011-08-04 Hu Yang Dendrimer hydrogels
EP2493458A2 (en) * 2009-10-30 2012-09-05 The Ohio State University Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
EP2531140B1 (en) * 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
EP2549986B1 (en) * 2010-03-24 2019-10-30 Northeastern University Multi-compartmental macrophage delivery
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011123591A1 (en) * 2010-03-31 2011-10-06 Wayne State University Injectable dendrimer hydrogel nanoparticles
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US8211450B2 (en) * 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
CA2810842C (en) 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
WO2012091680A1 (en) * 2010-12-30 2012-07-05 Nanyang Technological University A device for controlled release of a bioactive agent
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
CN104023749B (zh) 2011-09-14 2019-12-17 西北大学 能穿过血脑屏障的纳米缀合物
TWI462752B (zh) 2011-09-21 2014-12-01 Univ Nat Cheng Kung 包覆疏水性藥物之膠囊粒子製造方法
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013173657A1 (en) * 2012-05-16 2013-11-21 Micell Technologies, Inc. Low burst sustained release lipophilic and biologic agent compositions
US9737611B2 (en) 2012-05-21 2017-08-22 University Of Miami Dendrimer conjugates for coating cells
WO2014043576A1 (en) 2012-09-13 2014-03-20 Starpharma Pty Limited Method of treatment or prophylaxis of infections of the eye
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US20170073465A1 (en) * 2014-02-28 2017-03-16 Michigan Molecular Institute Sustained release composition using biobased biodegradable hyperbranched polyesters
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3137116B1 (en) * 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US10898593B2 (en) * 2014-05-13 2021-01-26 Yale University Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN108289872B (zh) 2015-10-29 2021-04-02 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途
CN108430514B (zh) 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
JP6986758B2 (ja) 2016-02-08 2021-12-22 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー−生体接着性ポリマーヒドロゲルナノ接着剤およびその使用
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
EP3615086A4 (en) * 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2018213125A1 (en) 2017-05-13 2018-11-22 The Johns Hopkins University Stromal derived factor 1 and it's use in the prevention and treatment of erectile dysfunction
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
MA50259A1 (fr) * 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
AU2019265632A1 (en) 2018-05-09 2021-01-07 Yale University Particles for spatiotemporal release of agents
PL239642B1 (pl) * 2018-08-16 2021-12-20 Pomorski Univ Medyczny W Szczecinie Kompozycja do doszklistkowego podawania białka leczniczego
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CA3163886A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
IL293605A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Hydroxyl polyamidoamine dendrimers modified with trihexylated n-acetylgalactosamine and methods of using them
CN111249533B (zh) * 2020-01-09 2021-01-08 中国人民解放军总医院 去铁敏缓释微泡修饰的复合孔径静电纺丝支架及其制备方法
CA3176523A1 (en) 2020-04-24 2021-10-28 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
JP2023522984A (ja) 2020-04-24 2023-06-01 アシュバッタ セラピューティクス, インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
US20230399368A1 (en) * 2020-10-23 2023-12-14 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
EP4251283A1 (en) 2020-11-27 2023-10-04 General Nanotherapeutics LLC Methods and composition for treatment of immune-mediated diseases
CA3224112A1 (en) * 2021-06-24 2022-12-29 David Feifel Psychedelic drug treatment of neuropsychiatric disorders and cerebral palsy
JP2024534501A (ja) 2021-09-21 2024-09-20 ザ・ジョンズ・ホプキンス・ユニバーシティー 細胞内送達のための小分子生物製剤のデンドリマーコンジュゲート
US20250049963A1 (en) 2021-12-20 2025-02-13 The Johns Hopkins University Glycosylated dendrimers for targeted intracellular delivery
US20250195672A1 (en) * 2022-04-05 2025-06-19 The Johns Hopkins University Dendrimer compositions for targeted delivery of therapeutics to neurons
JP2025523965A (ja) 2022-07-22 2025-07-25 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマーが可能にする標的化細胞内crispr/casシステム送達および遺伝子編集
CN119768187A (zh) 2022-08-26 2025-04-04 约翰霍普金斯大学 抗抑郁药和抗精神病药的树枝状大分子缀合物及其使用方法
KR20250051123A (ko) 2022-08-26 2025-04-16 더 존스 홉킨스 유니버시티 표적 전달을 위한 칸나비노이드 덴드리머 조성물
CN119923278A (zh) 2022-08-26 2025-05-02 约翰霍普金斯大学 用于靶向递送迷幻治疗剂的树枝状大分子组合物
EP4574146A1 (en) * 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases
IL330156A (en) 2023-12-18 2026-08-01 The Johns Hopkins Univ Dendrimer compositions for the treatment of atherosclerosis, obesity and metabolic syndromes
WO2025160171A1 (en) 2024-01-22 2025-07-31 The Johns Hopkins University Multivalent dendrimer conjugated protacs for cell-targeted targeted protein degradation
WO2025160546A1 (en) 2024-01-26 2025-07-31 The Johns Hopkins University Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025184657A1 (en) 2024-03-01 2025-09-04 The Johns Hopkins University Ha-dendrimer cornea formulation for regeneration of corneal tissue
WO2025193538A1 (en) 2024-03-11 2025-09-18 The Johns Hopkins University Dendrimer compositions for targeted delivery of gcpii inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
US6585956B2 (en) 1997-07-07 2003-07-01 The Dow Chemical Company Dendritic-platinate drug delivery system
WO1999042147A1 (en) 1998-02-23 1999-08-26 Massachusetts Institute Of Technology Biodegradable shape memory polymers
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
KR100379248B1 (ko) * 2000-12-04 2003-04-08 한국과학기술연구원 덴드리머를 이용한 나노 입자가 표면에 부착된무기-고분자 복합 소재 및 그 제조 방법
US7045367B2 (en) 2001-03-23 2006-05-16 Michigan Molecular Institute Nano-scaled dendrimer-based colorimetric biosensors
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6617040B2 (en) 2002-01-16 2003-09-09 The United States Of America As Represented By The Secretary Of The Navy Chemoselective dendrimeric compounds for use in chemical sensors
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
WO2003080121A1 (en) 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research Macromolecular compounds as potential anti-inflammatory agents
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
CA2518223A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
KR20060015534A (ko) * 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
EP1708752B1 (en) 2004-01-27 2012-02-22 University Of Southern California Polymer-bound antibody cancer therapeutic agent
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
EP1796537A4 (en) 2004-08-25 2012-03-07 Univ Michigan DENDRIMER BASED COMPOSITIONS AND METHOD FOR THEIR USE
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20090192227A1 (en) 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
MX339797B (es) 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US7432069B2 (en) 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
AU2007212700A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts RNA interference agents for therapeutic use
EP1864668B1 (en) * 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
CN101472612B (zh) 2006-06-14 2011-06-08 纽崔西亚公司 包含甘氨酸和乳铁蛋白的抗炎组合物及其应用
WO2008036787A1 (en) 2006-09-22 2008-03-27 C.R. Bard, Inc. Antimicrobial compositions containing gallium
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes

Also Published As

Publication number Publication date
US20110034422A1 (en) 2011-02-10
JP5484339B2 (ja) 2014-05-07
US20160279054A1 (en) 2016-09-29
WO2009046446A2 (en) 2009-04-09
US20200390694A1 (en) 2020-12-17
DK2214646T3 (da) 2021-10-04
WO2009046446A3 (en) 2009-06-04
EP2214646A2 (en) 2010-08-11
HUE055815T2 (hu) 2021-12-28
US11684569B2 (en) 2023-06-27
CA2701291A1 (en) 2009-04-09
US10463609B2 (en) 2019-11-05
EP2214646B1 (en) 2021-06-23
EP2214646A4 (en) 2014-08-27
US20170216200A1 (en) 2017-08-03
JP2010540664A (ja) 2010-12-24
PT2214646T (pt) 2021-09-29

Similar Documents

Publication Publication Date Title
BRPI0807453A2 (pt) Preparação sólida
DK2205737T3 (da) Mikromirer
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DE502007001207D1 (de) Elektrosaugkopf
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
DE602008000749D1 (de) Buschschneider
BRPI0814519A2 (pt) Organopolissiloxano
DK2125048T3 (da) Præparat
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
FI20075851A0 (fi) Muodostusosa
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
AT505058A3 (de) Türschliesssystem
DE602008001674D1 (de) Wimpernwickler
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE112008003196A5 (de) Handpipettiergerät
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung
DE502008003063D1 (de) Magnetventilinjektor